Ki H. Lee, MD

Executive Medical Director, Comprehensive Epilepsy Center and Child Neurology

Neuroscience Research

Expertise of Ki H. Lee, MD

Biography: Ki Hyeong Lee, MD, MS, is a board-certified neurologist and epileptologist with AdventHealth Medical Group and the Medical Director of AdventHealth for Children’s pediatric epilepsy center in Orlando. A leading provider of diagnostic and surgical techniques for addressing epilepsy and seizures, Dr. Lee completed three prestigious fellowships in clinical neurophysiology, epilepsy research and stroke at the Medical College of Georgia, Mayo Clinic Foundation in Minneapolis and Seoul National University Hospital in Korea, respectively. A noted researcher who regularly presents his work in published articles and international medical forums, he constantly seeks to advance the state of epilepsy patient care through medical breakthroughs and new technologies.
Education: Seoul National University College of Medicine
Fellowship: Medical College of Georgia
Specialty: Pediatric Neurology
Board Certifications: American Board of Psychiatry and Neurology

Associated Clinical Trials for Ki H. Lee, MD

NCT06132893

A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of the BHV7000 in Subjects with Refractory Focal Onset Epilepsy

This study is not currently enrolling.

Associated Conditions: Epilepsy

Research Area: Neuroscience Research

Research Location: Orlando

This is a research study to test a new investigational drug. An investigational drug is one that is not approved by the United States Food and Drug Administration (FDA). The main purpose of this study...
NCT05626634

A Phase 2, multicenter, open-label, long-term safety study of LP352 in subjects with developmental and epileptic encephalopathy who completed Study LP352-201 and are candidates for continuous treatment for up to 52 weeks.

This study is not currently enrolling.

Associated Conditions: Epilepsy

Research Area: Neuroscience Research

Research Location: Orlando

You, or you and the individual you care for, are being asked to take part in a research study because you have seizures associated with developmental and epileptic encephalopathy (DEE) and you have...
NCT05064878

A Phase 3, Randomized, Double-blind, Placebo-Controlled, Fixed-Dose, Multicenter Study to Examine the Efficacy and Safety of ZX008 in Subjects with CDKL5 deficiency disorder followed by an Open-Label Extension.

This study is not currently enrolling.

Associated Conditions: Epilepsy

Research Area: Neuroscience Research

Research Location: Orlando

The purpose of this informed consent form is to collect data about the non-paid caregiver of a subject that is participating in ZX008-2103 study. You, as the non-paid caregiver, are being asked to...

More clinical trials loaded
NCT05076838

An Open-Label, Single-Dose, Pharmacokinetics Study of VALTOCO with Open-Label Safety Period in Pediatric Subjects with Epilepsy

This study is not currently enrolling.

Associated Conditions: Pediatric

Research Area: Neuroscience Research

Research Location: Orlando

This is a research study to evaluate the pharmacokinetics (PK), safety and tolerability after a single intranasal dose of VALTOCO (diazepam nasal spray), followed by a long-term safety period, where...

Ki H. Lee, MD

Expertise of Ki H. Lee, MD

Associated Clinical Trials for Ki H. Lee, MD

A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of the BHV7000 in Subjects with Refractory Focal Onset Epilepsy

A Phase 2, multicenter, open-label, long-term safety study of LP352 in subjects with developmental and epileptic encephalopathy who completed Study LP352-201 and are candidates for continuous treatment for up to 52 weeks.

A Phase 3, Randomized, Double-blind, Placebo-Controlled, Fixed-Dose, Multicenter Study to Examine the Efficacy and Safety of ZX008 in Subjects with CDKL5 deficiency disorder followed by an Open-Label Extension.

An Open-Label, Single-Dose, Pharmacokinetics Study of VALTOCO with Open-Label Safety Period in Pediatric Subjects with Epilepsy